EAST BRUNSWICK, N.J., Oct. 14 Savient Pharmaceuticals, Inc. (Nasdaq: SVNT), announced today that the Company's Chief Medical Officer, Dr. Zeb Horowitz, will host a conference call and webcast on Wednesday, October 29, 2008 at 9:00 AM PT/12:00 PM ET to discuss the pegloticase presentations given at the American College of Rheumatology's 72nd Annual Scientific Meeting in San Francisco. A question and answer period will follow Dr. Horowitz's prepared remarks.
The webcast will be available through http://investor.savient.com. Please click on "Events & Webcasts" to access the event.
The call can also be accessed by dialing (888) 802-8577 (U.S. participants) or (973) 935-8754 (International participants). Callers should be prepared to reference conference ID number 68878067.
A replay and webcast of the call will be available two hours after the call is completed and can be accessed by dialing (800) 642-1687 (U.S.) or (706) 645-9291 (International). The replay access code is 68878067. The replay and webcast will be available through November 11, 2008. Please click on "Events & Webcasts" in the Investor Relations section of the site to access the replay.
ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The company's product development candidate, Puricase(r) (pegloticase) for treatment-failure gout, has reported positive Phase 1, 2 and 3 clinical data. Patient dosing in the Phase 3 clinical studies began in June 2006; patient enrollment was completed in March 2007; and the Phase 3 clinical studies were completed in October 2007. Savient has exclusively licensed worldwide rights to the technology related to Puricase from Duke University and Mountain View Pharmaceuticals, Inc. Savient's experienced management team is committed to advancing its pipeline and expanding its product portfolio by in-licensing late-stage compounds and exploring co-promotion and co-development opportunities that fit the Company's expertise in specialty pharmaceuticals and biopharmaceuticals with an initial focus in rheumatology. Savient also manufactures and supplies Oxandrin(r) (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. Further information on Savient can be accessed by visiting: http://www.savient.com.
CONTACT: Savient Pharmaceuticals, Inc. Mary Coleman (732) 418-9300 firstname.lastname@example.org Joele Frank, Wilkinson Brimmer Katcher Kelly Sullivan / Ed Trissel 212-355-4449 email@example.com or firstname.lastname@example.org
SOURCE Savient Pharmaceuticals, Inc.